Welcome to our dedicated page for Indaptus Therapeutics news (Ticker: INDP), a resource for investors and traders seeking the latest updates and insights on Indaptus Therapeutics stock.
Indaptus Therapeutics develops clinical-stage immunotherapies for cancer and viral infections using its Decoy bacterial platform. The company’s lead candidate, Decoy20, is based on attenuated and killed, non-pathogenic Gram-negative bacteria designed to activate innate and adaptive immune responses, with a focus on solid tumors.
Recurring news for Indaptus covers clinical updates from the INDP-D101 program, including Decoy20 evaluation as monotherapy and in combination with the PD-1 inhibitor tislelizumab. Company updates also include preclinical research on immune-cell activation, quarterly financial results, private placements, convertible notes and warrants, at-the-market financing, reverse stock split actions, Nasdaq compliance matters, and scientific or investor conference presentations.
Indaptus Therapeutics announced the successful dosing of the first patient in the multi-dose phase of its Phase 1 clinical trial for Decoy20, a novel immuno-oncology therapy targeting advanced solid tumors.
The trial aims to determine the safety and efficacy of Decoy20 when administered multiple times. The initial single-dose phase was well-tolerated, and results will be presented at the ASCO meeting. Decoy20 activates both the innate and adaptive immune systems using broad immune agonists derived from Gram-negative bacteria, aiming to offer a new approach to cancer treatment.
CEO Jeffrey Meckler emphasized the potential of Decoy20 to address unmet medical needs in cancer therapy. The company plans to advance the therapy into combination studies with checkpoint inhibitors based on promising preclinical results.
Indaptus Therapeutics, Inc. (Nasdaq: INDP) reported first quarter 2024 financial results and provided a corporate update, highlighting progress in its clinical development plans. The company announced positive results from its Phase 1 clinical trial of Decoy20 and plans to present a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2024. Financially, research and development expenses decreased by 15%, general and administrative expenses decreased by 9%, and loss per share improved. The company had cash and cash equivalents of $9.7 million as of March 31, 2024, with a cash runway expected to support operations through the third quarter of 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.